The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer

To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)

Inclusion Criteria:

• Age ≥ 18 years old
• male or female
• Patients with stage IV gastric cancer by pathology or cytology and imaging diagnosis , or after previous surgery or radiotherapy or chemotherapy in patients with stage IV gastric cancer progression , there RECIST criteria evaluable lesions ;
• ECOG performance status score 0-2 ;
• Expected survival time more than three months ;
• Adequate hematologic parameters and liver and kidney function ;
• Bone marrow : absolute neutrophil count (ANC) ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 / L, hemoglobin ≥ 80g / L;
• Liver: bilirubin ≤ 1.5 times the upper limit of normal , ALT AST values ≤ 2.5 times the upper limit of normal ;
• Renal : serum creatinine ≤ ULN ;
• Informed consent of patients or their agents , and signed informed consent.

Exclusion Criteria:

• For patients allergic to capecitabine ;
• Patients with CNS metastases
• Undermine the integrity of the upper gastrointestinal tract , malabsorption syndrome , or unable to take oral medication ;
• Patients with coronary heart disease , angina , myocardial infarction , arrhythmia, cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular disease ;
• Or in combination with other anti-tumor therapy in patients participating in clinical trials of other interventions ;
• Pregnancy or breast-feeding patients , or fertility without taking adequate contraceptive measures were ;
• The researchers believe that this test is not suitable for those who participate .